Dendreon's (DNDN) prostate cancer vaccine Provenge is under scrutiny again from longtime gadfly...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Dendreon's (DNDN) prostate cancer vaccine Provenge is under scrutiny again from longtime gadfly Marie Huber. She alleges that the studies by the company leading up to FDA approval for the drug are suspect and says she will present her finding to EU officials as they consider Provenge.